Safary Azam, Akbarzadeh-Khiavi Mostafa, Barar Jaleh, Omidi Yadollah
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Bioimpacts. 2023;13(4):269-273. doi: 10.34172/bi.2023.27494. Epub 2023 Jun 27.
Induced autoimmunity or autoinflammatory-like conditions as a rare vaccine-related adverse event have been reported following COVID-19 vaccination. Such inadvertent adverse reactions have raised somewhat concerns about the long-term safety of the developed vaccines. Such multifactorial phenomena may be related to the cross-reactivity between the viral-specific antigens with the host self-proteins through molecular mimicry mechanism and/or nonspecific bystander activation of the non-target antigen-independent immunity by the entities of the vaccine products. However, due to the low incidence of the reported/identified individuals and insufficient evidence, autoimmunity following the COVID-19 vaccination has not been approved. Thereby, it seems that further designated studies might warrant post-monitoring of the inevitable adverse immunologic reactions in the vaccinated individuals, especially among hypersensitive cases, to address possible immunological mechanisms induced by the viral vaccines, incorporated adjuvants, and even vaccine delivery systems.
接种新冠疫苗后，诱导自身免疫或自身炎症样病症作为一种罕见的疫苗相关不良事件已有报道。此类意外不良反应在一定程度上引发了对已研发疫苗长期安全性的担忧。这种多因素现象可能与病毒特异性抗原通过分子模拟机制与宿主自身蛋白的交叉反应和/或疫苗产品成分对非靶抗原非特异性旁观者免疫的激活有关。然而，由于报告/确认个体的发生率较低且证据不足，新冠疫苗接种后的自身免疫尚未得到认可。因此，似乎需要进一步开展特定研究，对接种疫苗个体，尤其是过敏个体中不可避免的不良免疫反应进行监测，以探讨病毒疫苗、所含佐剂甚至疫苗递送系统诱导的可能免疫机制。
